Dublin, Aug. 30, 2023 (GLOBE NEWSWIRE) -- The "Global Peptide Therapeutics Market (2023-2028) by Synthesis Technology, Drug Class, Route of Administration, API Type, Application, End User, and Geography, Competitive Analysis, Impact of Covid-19 and Ansoff Analysis" report has been added to ResearchAndMarkets.com's offering.
The global Peptide Therapeutics market is poised for substantial growth, with an estimated value of USD 32.84 billion in 2023, projected to reach USD 53.04 billion by 2028, exhibiting an impressive Compound Annual Growth Rate (CAGR) of 10.06% during the forecast period.
Market Overview
Peptides, short chains of amino acids, have shown great potential in targeting specific biological processes within the body. Their ability to mimic natural proteins and influence biological functions makes them a promising avenue for therapeutic development. Peptide-based treatments offer targeted and efficient alternatives to traditional medications, often with fewer side effects.
Market Dynamics
The global rise in cancer, cardiovascular diseases, and metabolic disorders has driven the demand for effective and targeted therapies. Peptide therapies, with their ability to precisely target disease-related processes, are emerging as potential solutions. These therapies are gaining traction as viable options for patients seeking more effective and safer treatment options for these serious conditions.
Advancements in biotechnology and drug development have paved the way for new platforms to create next-generation protein and peptide therapies. These platforms enable the design, manufacturing, and delivery of more stable, potent, and selective peptide medicines. As pharmaceutical companies invest in these advanced techniques, the peptide therapeutics market is experiencing rapid expansion, attracting both research and commercial investments.
Continued innovation in biotechnology and peptide research has unlocked new avenues for drug development. Ongoing research in new peptides and improved synthesis processes, coupled with substantial research and development investments, is resulting in more stable, efficient, and tailored treatments. The continuous technological advancement and financial commitment in the peptide sector offer significant potential for the development of advanced pharmaceuticals to address unmet medical needs.
Market Segmentations
The market is segmented based on Synthesis Technology (Hybrid Phase, Liquid Phase, Solid Phase), Drug Class (Calcitonins, Glucagon & Analogs, Insulins, Luteinizing Hormone-Releasing Hormone, Somatostatins, Vasopressin), Route of Administration (Parenteral, Oral), API Type (CMO, In-house), Application (Gastrointestinal Disorders, Neurological Disorders, Metabolic Disorders, Cancer, Other Applications), and End User (Hospitals, Pharmaceutical Industries, Research Laboratories).
Among these segments, Solid Phase Synthesis is a dominant method due to its versatility and scalability. Insulins hold a significant market share, driven by their critical role in diabetes treatment. The parenteral route of administration is preferred for peptide therapies due to their sensitivity to digestive breakdown. Pharmaceutical industries play a crucial role as end users, driving the creation and distribution of peptide therapies.
Recent Developments
Recent developments include the launch of Peptide Therapy Gel by CHOSEN by Dermatology for intense skin repair and rejuvenation, as well as Evonik's introduction of a next-generation peptide for biopharma applications.
Companies Mentioned
- AmbioPharm Inc.
- Amgen Inc.
- AstraZeneca PLC
- Bachem Holding Ag
- Bristol-Myers Squibb Company
- Corden Pharma GmbH
- Eli Lilly and Company
- F. Hoffmann-La Roche Ag
- GSK PLC
- Hemmo Pharmaceuticals Pvt. Ltd.
- Ipsen SA
- Merck & Co., Inc.
- Novartis International Ag
- Novo Nordisk AS
- Pfizer Inc.
- PolyPeptide Group
- Sanofi SA
- Takeda Pharmaceutical Co.Ltd.
- Teva Pharmaceutical Industries Ltd.
- Zealand Pharma AS
Conclusion
The global Peptide Therapeutics market is poised for remarkable growth, driven by increasing prevalence of diseases, advancements in biotechnology, and ongoing research and innovation in peptide development. While challenges exist, including stability issues of naturally occurring peptides and stringent safety regulations, opportunities abound for the industry to deliver targeted and efficient therapies to meet the evolving needs of patients.
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 128 |
| Forecast Period | 2023 - 2028 |
| Estimated Market Value (USD) in 2023 | $32.84 Billion |
| Forecasted Market Value (USD) by 2028 | $53.04 Billion |
| Compound Annual Growth Rate | 10.0% |
| Regions Covered | Global |
For more information about this report visit https://www.researchandmarkets.com/r/5e7x2n
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
